FeaturedMedia Release
Investigational New Drug application filed with FDA
Race Oncology has announced the US Food and Drug Administration has received its
FeaturedMedia Release
Principal Investigator appointed for Bisantrene trial
Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal
FeaturedMedia Release
Race appoints leading haematologist to support Bisantrene
Race Oncology is pleased to announce that it has executed a consulting agreement with Professor
FeaturedMedia Release
Race reaches agreement with TrueMed for Bisantrene sales in Israel
Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP)
FeaturedMedia Release
Race appoints BioSynergy to pursue Bisantrene licensing
Race Oncology is pleased to announce it has executed a services agreement with BioSynergy
Featured
Finance News Network interviews CEO Peter Molloy
CEO Peter Molloy spoke with Finance News Network about Bisantrene and Race Oncology’s
FeaturedMedia Release
Race appoints US consultant to drive partnering, investment, clinical funding
Race Oncology is pleased to announce that it has executed an agreement with Mr Tom Lee to
FeaturedMedia Release
Race signs agreement with NSF Health Sciences to file IND
Race Oncology is pleased to announce it has executed an agreement with Washington D.C –
FeaturedMedia Release
Bisantrene receives ‘Rare Paediatric Disease’ designation from FDA
Race Oncology is pleased to announce that it has received a letter from the FDA advising that
FeaturedMedia Release
Chart: Long-term survival case report of patients treated with Bisantrene Combination Therapy
The chart below details the long-term survival case report of two paediatric relapsed or